there is certainly an improvement between CD4 +, CD4 +/ CD8ratio between poorly- differentiated and well- classified teams ROC P worth (0.022, 0.341, 0.012) Sensitivity (0.857, 0.882), specificity (0.706, 0.857) correspondingly. with no differences between CD8 + poorly- differentiated and well- classified teams ROC P price (0.341). there is a significant difference between CD4 + between moderately – classified and well- differentiated groups ROC P value (0.038) Sensitivity (0.368), specificity (0,765). No considerable correlation ended up being obtained with clinicopathologic findings of OSCC. The study method uses blended techniques with a cross-sectional method and online survey sampling techniques (677 respondents), in December 2021-January 2022 in Indonesia. The tools utilized are the System Usability Scale and User Experience Questionnaire. The variables assessed range from the characteristics of participants, functionality, user experience, and answers to making use of applications qualitatively. Quantitative data were analysed descriptively in addition to consumer experience Questionnaire’s analysis tool. Qualitative data were analysed thematically. Analysis of the usability of Oncodoc’s m-health application is in the “acceptable” category (70.88), therefore the adjective rating is within the “Good” category. Evaluations associated with the relative quality of user experience are in the “good” and “very good” types. The average consumer experience scale is (mean LPA genetic variants ; SD) attractiveness (1.80; 0.99), perspicuity (1.82; 1.05), effectiveness (1.78; 1.09), reliability (1.56; 1.01), stimulation (1.81; 1.06), and novelty (1.32; 1.10). The conclusions Medical adhesive of the research are 1) the capacity to accommodate individual requirements, 2) usage obstacles, and 3) user expectations when it comes to Oncodoc application. Overall, the Oncodoc m-health application is acceptable to users. We recommend developing a cancer early detection application with an approach that refers to user needs for further research.Overall, the Oncodoc m-health application is appropriate to people. We advice developing cancer early detection application with a method that relates to user needs for additional study. The goal of the study would be to gauge the primary epidemiological characteristics of AML (morbidity, success, circulation by AML variants and age brackets) in 5 regions playing the analysis. This stat study had been carried out on patients diagnosed with intense myeloid leukemia in 5 parts of Kazakhstan, from January 2017 to December 2020. Compared to self-assessment of severe myeloid leukemia making use of a questionnaire, postoperative histopathology in customers with suspected acute myeloid leukemia. The questionnaire, published by artificial cleverness, is grouped into categories “risk” and “no risk”. Statistical handling and analysis of information ended up being completed with the analytical package SAS 9.4. Types of reporting data, standardization of morbidity were used. According to the standard morbidity indicators received (from 1.39 to 2.43 per 100 thousand population), we are able to say that the authorized incidence of AML remains reasonable. This value practically will not differ from the occurrence of AML (2.71) according to the Kazakhstan Cancer Registry for 2016 and it is somewhat lower than the data of European and US registries (4-5 situations per 100 thousand residents per year). This study identified specific places with a top chance of acute myeloid leukemia in Eastern Kazakhstan, in addition to spatial inequality in their circulation utilizing the development for this infection. These results can be useful in building any strategy for giving an answer to a high risk of cancer in certain areas.This study identified specific places with a higher threat of intense myeloid leukemia in Eastern Kazakhstan, as well as spatial inequality within their circulation with the formation of the illness. These outcomes they can be handy in building any technique for responding to increased risk of cancer tumors in certain areas. Purpose of this study will be evaluate the efficacy of inhomogeneity modifications calculated by radiotherapy treatment preparation system (TPS) using various densities of products. Gammex Computed tomography electron thickness inserts (EDI’s; 14 no’s) were used to generate the CT to ED curve with high rate GE CT scanner by noting along the respective HU values of each rod. Treatment plans were created in XiO TPS with three inhomogeneous phantoms (comprising combination of liquid, lung and bone tissue equivalent slabs) with different field sizes as well as EDI (8 no’s) inserted in slots of acrylic tray and validation was learn more completed utilizing 2D range detector with 20cm×20cm industry dimensions for 200 MU. Aim dose and fluence dimensions had been carried with inhomogeneous phantoms combinations and EDI’s (positioned on the locally fabricated field filled with water method). The mean percentage deviations with standard deviation of calculated point doses against calculated people acquired with 2D array detector at iso-center jet for many three inhomogeneous phantom combinations were found become -1.13%±0.13%, -3.51%±0.14% and -0.63%±0.27per cent correspondingly. On point doses assessed under each individual EDI, over all percentage deviation with standard deviation seen is -2.04% ± 1.1%. Targeting breast cancer stem cells because of the CD44+/CD24- phenotype is important for total eradication of cancer tumors cells due to its Self-renewal, differentiation, and healing resistance ability.